These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31401638)

  • 21. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of the pharmacogenetics of HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nácher I; Soriano V
    Pharmacogenomics J; 2006; 6(4):234-45. PubMed ID: 16462814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of antiretroviral therapy.
    Barreiro P; Fernández-Montero JV; de Mendoza C; Labarga P; Soriano V
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1119-30. PubMed ID: 24941049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.
    Lubomirov R; Csajka C; Telenti A
    Pharmacogenomics; 2007 Jun; 8(6):623-33. PubMed ID: 17559351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of anti-HIV drugs.
    Telenti A; Zanger UM
    Annu Rev Pharmacol Toxicol; 2008; 48():227-56. PubMed ID: 17883329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].
    ;
    Enferm Infecc Microbiol Clin; 2007 Jan; 25(1):32-53. PubMed ID: 17261244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of adverse effects due to antiretroviral drugs.
    Vidal F; Gutiérrez F; Gutiérrez M; Olona M; Sánchez V; Mateo G; Peraire J; Viladés C; Veloso S; López-Dupla M; Domingo P
    AIDS Rev; 2010; 12(1):15-30. PubMed ID: 20216907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of antiretrovirals.
    Tozzi V
    Antiviral Res; 2010 Jan; 85(1):190-200. PubMed ID: 19744523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV pharmacogenetics in clinical practice: recent achievements and future challenges.
    Tozzi V; Libertone R; Liuzzi G
    Curr HIV Res; 2008 Nov; 6(6):544-54. PubMed ID: 18991620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacogenetics of antiretroviral therapy 2008: toward personalized treatment?].
    Vidal Marsal F
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():1-3. PubMed ID: 18680689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Bayesian approach for investigating the pharmacogenetics of combination antiretroviral therapy in people with HIV.
    Jin W; Ni Y; Spence AB; Rubin LH; Xu Y
    Biostatistics; 2024 Oct; 25(4):1034-1048. PubMed ID: 38365980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?
    Masimirembwa C; Dandara C; Leutscher PD
    OMICS; 2016 Oct; 20(10):575-580. PubMed ID: 27627692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of HIV therapy: challenges for tailoring treatment in genetically complex populations.
    de Almeida Velozo C; Cardoso CC
    Pharmacogenomics; 2022 Feb; 23(3):157-159. PubMed ID: 35023374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
    Arab-Alameddine M; Décosterd LA; Buclin T; Telenti A; Csajka C
    Expert Opin Drug Metab Toxicol; 2011; 7(5):609-22. PubMed ID: 21500966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
    Obiako OR; Murktar HM; Ogoina D
    Niger J Med; 2010; 19(4):352-60. PubMed ID: 21526620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)].
    Miró JM; Antela A; Arrizabalaga J; Clotet B; Gatell JM; Guerra L; Iribarren JA; Laguna F; Moreno S; Parras F; Rubio R; Santamaría JM; Viciana P
    Enferm Infecc Microbiol Clin; 2000; 18(7):329-51. PubMed ID: 11109725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetic testing in oncology: a Brazilian perspective.
    Suarez-Kurtz G
    Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e565s. PubMed ID: 30328952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.